BioCentury
ARTICLE | Regulation

FDA approval of Regeneron’s Evkeeza brings new drug class to HoFH patients

February 12, 2021 2:06 AM UTC

Regeneron’s Evkeeza evinacumab-dgnb gained FDA approval Thursday as the first ANGPTL3 inhibitor to treat homozygous familial hypercholesterolemia, offering a new mechanism of action to patients who don’t respond to statins or PCSK9 therapy. 

The mAb is approved as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat HoFH patients ages 12 and older. The ultra-rare genetic disorder affects about 1,300 U.S. patients...

BCIQ Company Profiles

Regeneron Pharmaceuticals Inc.

BCIQ Target Profiles

Angiopoietin-like 3 (ANGPTL3)